- 全部删除
- 您的购物车当前为空
INX-315, an orally active and selective CDK2 inhibitor, induces cell cycle arrest in the G1 phase, reduces CDK2 substrate phosphorylation, and inhibits tumor growth dose-dependently in xenograft mouse models. INX-315 may be used in cancer research [1].
为众多的药物研发团队赋能,
让新药发现更简单!
INX-315, an orally active and selective CDK2 inhibitor, induces cell cycle arrest in the G1 phase, reduces CDK2 substrate phosphorylation, and inhibits tumor growth dose-dependently in xenograft mouse models. INX-315 may be used in cancer research [1].
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 412 | In stock | |
5 mg | ¥ 993 | In stock | |
10 mg | ¥ 1,490 | In stock | |
25 mg | ¥ 2,380 | In stock | |
50 mg | ¥ 4,560 | In stock | |
1 mL x 10 mM (in DMSO) | ¥ 1,090 | In stock |
INX-315 相关产品
产品描述 | INX-315, an orally active and selective CDK2 inhibitor, induces cell cycle arrest in the G1 phase, reduces CDK2 substrate phosphorylation, and inhibits tumor growth dose-dependently in xenograft mouse models. INX-315 may be used in cancer research [1]. |
分子量 | 427.48 |
分子式 | C19H21N7O3S |
CAS No. | 2745060-92-6 |
颜色 | White |
物理性状 | Solid |
存储 | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
评论内容